Kruglova L S, Pereverzina N O, Rudneva N S, Kamynina N N, Oynotkinova O Sh
Central State Medical Academy of the Administrative Department of the President of Russia, Moscow, 121359, Russia.
Tula State University, Tula, 300012, Russia.
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2021 Aug;29(Special Issue):1381-1387. doi: 10.32687/0869-866X-2021-29-s2-1381-1387.
Currently, the ongoing pandemic of the novel coronavirus infection is still a major public health problem worldwide. The questions of immunosuppressive therapy of patients with psoriasis and psoriatic arthritis, the possibility of vaccination against the background of the use of genetically engineered drugs remain open. The article is of an overview nature and includes up-to-date information on the feasibility and safety of the use of genetically engineered biological drugs in patients with psoriasis in a pandemic (COVID-19). According to the international recommendations of the National Psoriasis Foundation COVID-19 Task Force expert group, treatment of psoriasis and/or PsA does not significantly alter the risk of SARS-CoV-2 infection and does not lead to worse prognosis of COVID-19. Therefore, patients not infected with SARS-CoV-2 should continue biological or other systemic therapy for psoriasis and/or PsA. According to a registry from 25 countries, hospitalization with SARS-CoV-2 infection was more common in patients receiving nonbiological systemic therapy than in patients receiving BAs. Thus, genetically engineered biological drugs do not appear to cause an increased risk of coronavirus infection and do not determine a more severe course. With regard to vaccination of patients with psoriasis, many issues require further study. According to international agreements, vaccination is not contraindicated in patients with psoriatic disease. However, there is still insufficient data on how the treatment of psoriatic disease affects vaccination. Avoiding COVID-19 or reducing the severity of infection following SARS-CoV-2 vaccination is thought to far outweigh any risk directly related to vaccination complications.
目前，新型冠状病毒感染的大流行仍是全球主要的公共卫生问题。银屑病和银屑病关节炎患者的免疫抑制治疗问题，以及在使用基因工程药物背景下进行疫苗接种的可能性仍未解决。本文是一篇综述性质的文章，包含了关于基因工程生物药物在大流行（新冠疫情）期间用于银屑病患者的可行性和安全性的最新信息。根据美国国家银屑病基金会新冠疫情特别工作组专家小组的国际建议，银屑病和/或银屑病关节炎的治疗不会显著改变感染新冠病毒的风险，也不会导致新冠疫情的预后变差。因此，未感染新冠病毒的患者应继续接受银屑病和/或银屑病关节炎的生物治疗或其他全身治疗。根据来自25个国家的一项登记数据，接受非生物全身治疗的患者比接受生物制剂治疗的患者更易因感染新冠病毒而住院。因此，基因工程生物药物似乎不会增加冠状病毒感染的风险，也不会导致病情更严重。关于银屑病患者的疫苗接种，许多问题仍需进一步研究。根据国际协议，银屑病患者接种疫苗并无禁忌。然而，关于银屑病的治疗如何影响疫苗接种，目前仍缺乏足够的数据。人们认为，避免感染新冠病毒或减轻感染新冠病毒后的严重程度，远比与疫苗接种并发症直接相关的任何风险重要得多。
